Dermapharm: Supervisory Board and major shareholder Wilhelm Beier bought shares worth €53.82 million. What is the plan?

Dermapharm (i) is a leading manufacturer of branded pharmaceuticals and other health products. It markets medicines with over 390 active pharmaceutical ingredients that are produced in-house. The company is a market leader in Germany for prescription dermatologicals as well as vitamins. By 2025, it is expected to achieve revenues of €1.16 to €1.2 billion with an EBITDA of €322 to €332 million. With a KGV26e of 16, the valuation is actually fair, unless growth picks up significantly. Dermapharm itself has recently built the foundation for...